Mouse lymphocytes incubated with micromolar concentrations of adenosine or 3-deazaadenosine, in medium supplemented with L-homocysteine, rapidly accumulated supramillimolar concentrations of S-adenosylhomocysteine (Ado~cy) or S-deazaadenosylhomocysteine (c3AdoHcy), respectively. Lymphocytes thus preloaded with Adenosine (Ado) and its structural analogs have been shown to affect a large number of physiological processes, and various biochemical effects have been reported in attempts to elucidate the mechanisms of action of these compounds (1-4). Two such biochemical effects of Ado-like compounds are particularly notable: (i) an increase in cellular cyclic AMP (cAMP) due to occupancy of an Ado receptor on the cell surface and consequent activation of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] (1-4); and (ii) an increase in cellular S-adenosylhomocysteine (AdoHcy) or an analog thereof, due either to inhibition of AdoHcy hydrolase (EC 3.3.1.1) or to condensation of the ribonucleoside with L-homocysteine (Hcy) via this enzyme (5-7).
fold) cyclic AMP responses to prostaglandin El, adenosine, 2- chloroadenosine, isoproterenol, and cholera toxin. This enhancement of cyclic AMP response by intracellular AdoHcy or c3AdoHcy was attributable both to amplification of the activity of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] and to inhibition of cyclic AMP phosphodiesterase (3',5'-cyclic-nucleotide 5'-nucleotidohydrolase, EC 3.1.4.17). Basal and prostaglandin E1-and isoproterenol-stimulated activities of adenylate cyclase, assayed in lymphocyte homogenates, were increased 1.3-to 2.0-fold after treatment of the cells with homocysteine plus either adenosine or 3-deazaadenosine. AdoHcy and c3AdoHcy were found to be competitive inhibitors (with KR values of 1.7 and 4.8 mM, respectively) of the highaffinity cyclic AMP phosphodiesterase present in lymphocyte homogenates. It is evident, therefore, that increased cellular levels of Ado cy or c3AdoHcy can affect cellular physiology via perturbation of cyclic AMP metabolism as well as via inhibition of S-adenosylmethionine-dependent methylation reactions.
Adenosine (Ado) and its structural analogs have been shown to affect a large number of physiological processes, and various biochemical effects have been reported in attempts to elucidate the mechanisms of action of these compounds (1) (2) (3) (4) . Two such biochemical effects of Ado-like compounds are particularly notable: (i) an increase in cellular cyclic AMP (cAMP) due to occupancy of an Ado receptor on the cell surface and consequent activation of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] (1-4); and (ii) an increase in cellular S-adenosylhomocysteine (AdoHcy) or an analog thereof, due either to inhibition of AdoHcy hydrolase (EC 3.3.1.1) or to condensation of the ribonucleoside with L-homocysteine (Hcy) via this enzyme (5) (6) (7) .
In physiological studies concerning Ado and its analogs, it is common practice to use auxiliary compounds as probes to help elucidate the biochemical mechanism by which an Adolike compound is causing a particular biological effect. For example, potentiation of a physiological effect of Ado by a nonmethylxanthine inhibitor of cAMP phosphodiesterase (3',5'-cyclic-nucleotide 5'-nucleotidohydrolase, EC 3.1.4.17), or antagonism of such an effect by a methylxanthine, is considered to provide evidence for a mechanism involving cAMP as an intracellular mediator (1) (2) (3) (4) . Similarly, potentiation by Hcy of a physiological effect caused by an Ado-like compound
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has recently come to be accepted as evidence for a cAMPindependent mechanism involving inhibition of one or more methyltransferases by high intracellular levels of AdoHcy or an analog thereof (6, (8) (9) (10) (11) (12) (13) (14) (15) (17) . 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724) was provided by Herbert Sheppard (Hoffmann-La Roche) and 2'-deoxycoformycin was from the Drug Development Branch (Developmental Therapeutic Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD). Other materials were from sources identified elsewhere (10, 12, (18) (19) (20) .
Cells. Cytolytic lymphocytes were obtained from CD-I mice 10 or 11 days after intraperitoneal injection of 3 X 107 C57BL leukemia EL4 cells (18) . Normal spleen lymphocytes were prepared by mincing spleens from CD-I mice in cold medium [Dulbecco's phosphate-buffered sWline supplemented with 10% fetal calf serum (heat-inactivated)] and forcing the tissue through a fine-mesh nylon filter. This cell preparation was incubated briefly in cold hypotonic (0.2%) saline to lyse erythrocytes, and adherent cells were removed by passage over a column of glass wool (18) . The nonadherent cells from these columns were once again incubated in cold hypotonic saline to eliminate residual erythrocyte contamination and were then washed with cold medium prior to their use in the various experiments.
Analytical Procedures. Cellular levels of AdoHcy and c3AdoHcy were determined by reversed-phase high-performance liquid chromatography (10) . cAMP present in acidsoluble extracts of cells was quantitated by radioimmunoassay after purification of the extracts on sequential columns of alu- Cytolytic lymphocytes (8.6 X 106 cells per 5.0 ml of medium) were preincubated for 60 min at 370C in the presence of erythro-9-[3-(2-hydroxynonyl)]adenine (EHNA) (7.9 MM) plus the specified agents. The cells were then harvested by centrifugation, washed twice, resuspended to original volume in drug-free medium, and incubated for 30 min with the indicated stimulator of adenylate cyclase. The cell suspensions were then acid-extracted for cAMP determinations. All incubations were performed in duplicate and each column-purified extract was radioimmunoassayed in duplicate for cAMP. Each value represents the mean ± SEM for four determinations.
* Erythro-9-[3-(2-hydroxynonyl)Jadenine (EHNA) (7.9 AM) was added to the cells together with the Ado. t Unlike the other stimulators examined, cholera toxin was added to the cells at the start of the 60-min preincubation phase of the experiment and non-cell-associated cholera toxin was removed by the washing procedure which preceded the 30-min stimulation phase of the experiment.
chloroadenosine, isoproterenol, and cholera toxin ( in their enhanced cAMP response to PGE1 after treatment with c3Ado plus Hcy (data not shown). Fig. 1 shows the effect of lymphocyte pretreatment with c3Ado plus Hcy on the time-course of the cAMP response to isoproterenol. The control cells exhibited a very small but reproducible increase in cAMP which was maximal at the earliest time (2 min) tested after the addition of isoproterenol (4.0MAM).
The c3AdoHcy-containing cells also exhibited a maximal cAMP response to isoproterenol at 2 min, but in this case the cAMP response was 12-fold higher than that of the control cells. Results identical to those in Fig. 1 were obtained at a 5-fold higher concentration of isoproterenol, indicating that'4.0 MM isoproterenol is saturating under these experimental conditions.'
Although the results presented thus far were obtained after a 60-min pretreatment with a ribonucleoside plus Hcy (in order to magnify the effect under study), a 5.0-min pretreatment of lymphocytes with c3Ado (10 ,uM) (Fig. 2) ; at cAMP concentrations abov'e 0.5 MM the double reciprocal plot acquired a marked downward curvature (results not shown). As shown in Fig. 2 , AdoHcy proved to be a competitive inhibitor of the high-affinity cAMP phosphodiesterase, yielding a Ki value of 1.7 mM. c3AdoHcy was also shown to be a competitive inhibitor of cAMP phosphodiesterase with Ki = 4.8 nrM (results not shown). Pretreatment of lymphocytes for 60 min with c3Ado (10 ,M) and Hcy (200 MM) had no effect upon the specific activity of cAMP phosphodiesterase assayed subsequently in dilute homogenates of these cells. Several compounds structurally related to AdoHcy and c3AdoHcy were also tested as inhibitors of lymphocyte cAMP phosphodiesterase (Table 3) . S-Adenosylmethionine (AdoMet) and adenosine were more inhibitory than AdoHcy; adenine was somewhat less inhibitory than these compounds. c3Ado was a better inhibitor than c3AdoHcy. 1-Methyl-3-isobutylxanthine (MIX) and Ro 20-1724 were clearly superior to all of these compounds as inhibitors of cAMP phosphodiesterase.
Effect of AdoHcy and c3AdoHcy on Adenylate Cyclase. Pretreatment (60 min) of lymphocytes with Hcy plus either Ado' or c3Ado resulted in a 2-fold increase, relative to controls, in the basal activity of adenylate cyclase assayed in cell homogenates (Table 4 ). The activities of PGE1-and isoproterenol-stimulated adenylate cyclase were also greater from the Ado/Hcy-and c3Ado/Hcy-treated cells. This effect on adenylate cyclase was not observed when either Hcy or the ribonucleoside (Ado or c3Ado) was omitted from these cellular incubations. This effect of cellular drug treatment on cyclase activity was not due to inhibition of cAMP phosphodiesterase present in the cell homogenates because the latter enzyme was completely inhibited by the high concentration (1.0 mM) of MIX which was included routinely in the cyclase assay mixture. Moreover, the direct addition of 5.0 mM AdoHcy to the assay of a lymphocyte homogenate was without effect on adenylate cyclase activity [for this experiment the lymphocytes were pretreated with 2'-deoxycoformycin and 9-/3-D-arabinofuranosyladenine (see Materials and Methods) to inactivate AdoHcy hydrolase and to prevent the degradation of AdoHcy during the cyclase assay]. The drug-induced alteration of adenylate cyclase does not appear to be due to the formation of a cytosolic activator because the effect of cellular pretreatment with c3Ado and Hcy on cyclase activity was fully retained by sucrose gradientpurified membranes (results not shown). 
DISCUSSION
These results demonstrate that exposure of mouse lymphocytes to either Ado or c3Ado, in the presence of Hcy, causes a marked enhancement in the responsiveness of these cells to various activators of adenylate cyclase. This enhancement of cellular cAMP response is apparently due to the intracellular accumulation of AdoHcy or c3AdoHcy because the formation of these nucleosidylhomocysteine metabolites and the effects on cellular cAMP metabolism are both dependent upon the simultaneous addition of a ribonucleoside (Ado or c3Ado) and Hcy to the cells. Intracellular AdoHcy or c3AdoHcy appears to augment the cellular cAMP response due both to inhibition of cAMP degradation and to enhancement of cAMP produc- AdoMet has been reported to be increased 2-to 3fold in cells treated with Ado (6) or c3Ado (10) and, like AdoHcy, is also an inhibitor of cAMP phosphodiesterase (Table 3 ). However, because basal cellular levels of AdoMet are less than 100 nmol/g of wet tissue (26) , it seems unlikely that AdoMet contributes in a major way to the cAMP effects described in this report.
The mechanism whereby intracellular AdoHcy or c3AdoHcy effects an increase in the activity of adenylate cyclase is not known. This effect may be due to favorable changes in the microenvironment of this enzyme in the cell membrane resulting from inhibition of phospholipid methyltransferases by AdoHcy or c3AdoHcy (27, 28) . It is possible that the influence of AdoHcy and c3AdoHcy on adenylate cyclase in intact cells is actually much greater than the 2-fold effect observed in broken cells and that disruption of the cells damages the critical molecular interactions responsible for the augmentation of cyclase activity; a similar suggestion has recently been put forth to explain the effects of colchicine on cellular levels of cAMP (29) .
Lymphocytes preloaded with c3AdoHcy exhibited a transitory cAMP response to isoproterenol (Fig. 1) . This result indicates that the enhancement of cAMP response by intracellular c3AdoHcy (or AdoHcy) is not due to attenuation of the process Normal spleen lymphocytes (4.0 X 108 cells per 100 ml of medium) were incubated for 60 min at 370C with the specified additives and then washed free of exogenous drugs and homogenized for assay of adenylate cyclase. The concentrations of GTP, PGE1, and isoproterenol present in the cyclase assays were 100, 100, and 10 AM, respectively. Each value represents the mean of two determinations.
* Erythro-9-[3-(2-hydroxynonyl)Jadenine (EHNA) ( (8, 12, 13) , lymphocyte-mediated cytolysis (10, 12) , concanavalin A-stimulated histamine release (11) , phagocytosis (9) , and immunoglobulin capping on lymphocyte membranes (15) , and to be potentiated in these inhibitbry activities by Hcy. In each of these studies, the observed potentiation by Hcy of a physiological effect of Ado or c3Ado has been interpreted as evidence for a biochemical mechanism involving inhibition of a critical methyltransferase by the AdoHcy or c3AdoHcy formed metabolically. However, in view of the results described in the present report, it is now evident that the above mechanistic interpretation may be oversimplified and that an involvement of cAMP should be considered. This is especially true because almost all of the cellular functions mentioned above are known to be inhibited by agents that cause an increase in cellular cAMP. Particularly pertinent to this discussion is the recent observation that chemotactic factors cause a transitory increase in cAMP in human neutrophils and that MIX inhibits factorinduced release of granule enzymes, apparently by enhancing the factor-induced increase in cAMP (30) .
Recognition that AdoHcy can markedly perturb cAMP metabolism provides yet another possible mechanism for the causal relationship between adenosine deaminase deficiency and severe combined immunodeficiency disease (31) . Evidence has been described for the irreversible inactivation of AdoHcy hydrolase by increased levels of 2'-deoxyadenosine in adenosine deaminase-deficient patients (25, 32) . Because the hydrolase represents the only known pathway for AdoHcy catabolism (5, 33) , and because intact AdoHcy does not readily diffuse across cell membranes (33, 34) 
